1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Drug Metabolite

Drug Metabolite

Drug metabolite results when a drug is metabolized into a modified form which continues to produce effects. Drug metabolism redox reactions such as heteroatom dealkylations, hydroxylations, heteroatom oxygenations, reductions, and dehydrogenations can yield active metabolites, and in rare cases even conjugation reactions can yield an active metabolite.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-138253R
    2′,2′-Difluorodeoxyuridine (Standard)
    2′,2′-Difluorodeoxyuridine (Standard) is the analytical standard of 2′,2′-Difluorodeoxyuridine. This product is intended for research and analytical applications. 2’,2’-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2’,2’-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro. 2’,2’-Difluorodeoxyuridine arrests cell cycle at the early S phase and induces apoptosis in cancer cells.
    2′,2′-Difluorodeoxyuridine (Standard)
  • HY-148375
    Abiraterone sulfate
    98.87%
    Abiraterone sulfate is a metabolite of Abiraterone (HY-148377). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity.
    Abiraterone sulfate
  • HY-117433S
    4-Hydroperoxy Cyclophosphamide-d4
    4-Hydroperoxy Cyclophosphamide-d4 is the deuterium labeled 4-Hydroperoxy cyclophosphamide. 4-Hydroperoxy cyclophosphamide is the active metabolite form of the proagent Cyclophosphamide. 4-Hydroperoxy cyclophosphamide crosslinks DNA and induces T cell apoptosis independent of death receptor activation, but activates mitochondrial death pathways through production of reactive oxygen species (ROS). 4-Hydroperoxy cyclophosphamide has the potential for lymphomas and autoimmune disorders.
    4-Hydroperoxy Cyclophosphamide-d<sub>4</sub>
  • HY-103005S
    Ramelteon metabolite M-II-d3
    ≥99.0%
    Ramelteon metabolite M-II-d3 is the deuterium labeled Ramelteon metabolite M-II. Ramelteon metabolite M-II is the major metabolite of Ramelteon, with IC50s of 208 pM, 1470 pM for human melatonin receptors (MT1 or MT2). Ramelteon is a selective melatonin agonist.
    Ramelteon metabolite M-II-d<sub>3</sub>
  • HY-100638A
    RPR132595A hydrochloride
    99.46%
    RPR132595A (NPC) hydrochloride is an active metabolite of CPT-11, which is generated by cytochrome P-450 3A4 (CYP3A4) and finally excreted through urine.
    RPR132595A hydrochloride
  • HY-N8210
    Homoeriodictyol
    99.83%
    Homoeriodictyol is an orally active, bitter-tasting flavanone that can penetrate the blood-brain barrier. Homoeriodictyol enhances synaptic-related protein expression through NCOA4-mediated ferritin autophagy. Homoeriodictyol improves memory impairment in mice by inhibiting the NLRP3 inflammasome. Homoeriodictyol protects human endothelial cells from oxidative damage by activating Nrf2 and inhibiting mitochondrial dysfunction. Homoeriodictyol enhances ROS activity and induces apoptosis, exhibiting anticancer effects. Homoeriodictyol inhibits the survival and migration of androgen-resistant prostate cancer cells in vitro. Homoeriodictyol exerts antinociceptive activity in mice in vivo.
    Homoeriodictyol
  • HY-W040705
    2-(Methylamino)benzoic acid
    99.80%
    2-(Methylamino)benzoic acid is the main metabolite of methyl-N-methylanthranilates (MMA) (HY-76705) and is the compound in which the ester group is converted. MMA can be isolated from citrus fruits and has potential analgesic activity. 2-(Methylamino)benzoic acid was used to detect the metabolic levels of MMA in rat liver.
    2-(Methylamino)benzoic acid
  • HY-113456S
    Leukotriene D4-d5
    98.4%
    Leukotriene D4-d5 is the deuterium labeled Leukotriene D4. Leukotriene D4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A) produced by the metabolism of LTC4 by γ-glutamyl transpeptidase. Leukotriene D4 is the first cysteinyl-leukotriene metabolite of LTC4. Leukotriene D4-induced bronchoconstriction and enhanced vascular permeability contribute to the pathogenesis of asthma and acute hypersensitivity.
    Leukotriene D4-d<sub>5</sub>
  • HY-B0601
    Tafluprost acid
    Chemical 99.80%
    Tafluprost acid (AFP-172), an active metabolic form of Tafluprost, is a selective prostanoid FP receptor agonist. Tafluprost acid shows a high affinity for human prostanoid FP receptor with Ki and EC50 values of 0.4 nM and 0.53 nM, respectively. Tafluprost acid has 126 times weaker binding affinity for prostanoid EP3 receptor (IC50=67 nM) than for the prostanoid FP receptor. Tafluprost acid can be used in the research of glaucoma.
    Tafluprost acid
  • HY-148682
    18β-Glycyrrhetyl-3-O-sulfate
    98.01%
    18β-Glycyrrhetyl-3-O-sulfate (Glycyrrhetic acid 3-O-(hydrogen sulfate)) is a potent type 2 11β-hydroxysteroid dehydrogenase (11β-HSD2) inhibitor with an IC50 of 0.10 µM using rat kidney microsome. 18β-Glycyrrhetyl-3-O-sulfate is the major metabolite of Glycyrrhetinic acid (GA). 18β-Glycyrrhetyl-3-O-sulfate is the substrate of organic anion transporter (OAT) 1 and OAT3. 18β-Glycyrrhetyl-3-O-sulfate has anti-inflammatory effects and has the potential for pseudohyperaldosteronism research.
    18β-Glycyrrhetyl-3-O-sulfate
  • HY-B0459A
    Scopine hydrochloride
    99.69%
    Scopine hydrochloride is a metabolite of Scopolamine (HY-N0296) and brain-targeting compound. Scopine hydrochloride significantly increases the brain exposure of Chlorambucil (HY-13593) and enhances its anti-glioma activity. Scopine hydrochloride can be used in targeted therapy research for brain gliomas.
    Scopine hydrochloride
  • HY-133781
    cis-Clopidogrel-MP derivative
    cis-Clopidogrel-MP derivative (Clopidogrel-MP-AM) is a 3’-methoxyacetophenone derivative of Clopidogrel active metabolite. Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor.
    cis-Clopidogrel-MP derivative
  • HY-109054A
    O-Desmethyltramadol hydrochloride
    99.79%
    O-Desmethyltramadol (hydrochloride) is a primary active metabolite of Tramadol. O-Demethyltramadol is mainly responsible for its µ-opioid receptor-related analgesic effect. Tramadol is metabolized to O-Demethyltramadol mainly by the cytochrome P450 (CYP) 2D6 enzyme.
    O-Desmethyltramadol hydrochloride
  • HY-19555
    Seco Rapamycin
    Seco Rapamycin (Secorapamycin A) is the ring-opened product of Rapamycin. Seco-rapamycin is reported not to affect the mTOR function.
    Seco Rapamycin
  • HY-113083
    Acetaminophen glucuronide
    ≥99.0%
    Acetaminophen glucuronide (APAP-glu) is an inactive glucuronide metabolite of Acetaminophen (HY-66005). Acetaminophen is a selective cyclooxygenase-2 (COX-2) inhibitor and a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor.
    Acetaminophen glucuronide
  • HY-118472
    Benazeprilat
    99.54%
    Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage.
    Benazeprilat
  • HY-100662
    Didesethyl chloroquine
    99.91%
    Didesethyl chloroquine (Bisdesethylchloroquine) is a major metabolite of the antimalarial agent Chloroquine. Didesethyl chloroquine is a potent myocardial depressant.
    Didesethyl chloroquine
  • HY-135910
    3,4-Dehydro Cilostazol
    98.09%
    3,4-Dehydro Cilostazol (OPC-13015) is an active metabolite of Cilostazol (CLZ; HY-17464). 3,4-Dehydro Cilostazol is used for pharmacokinetic study.
    3,4-Dehydro Cilostazol
  • HY-131479
    Threo-dihydrobupropion hydrochloride
    99.00%
    Threo-dihydrobupropion hydrochloride is a primary metabolite of Bupropion. Threo-dihydrobupropion hydrochloride can be used for the research of the depression, behavioral, and biochemistry.
    Threo-dihydrobupropion hydrochloride
  • HY-W394903
    GS-829845
    99.91%
    GS-829845 is a major, active metabolite of Filgotinib (HY-18300). GS-829845 is a JAK1 preferential inhibitor but is approximately 10-fold less potent than the parent and with a longer half-life.
    GS-829845
Cat. No. Product Name / Synonyms Application Reactivity